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Abstract
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart. HCM is characterized by a
wide range of clinical expression, ranging from asymptomatic mutation carriers to sudden cardiac death as the first
manifestation of the disease. Over 1000 mutations have been identified, classically in genes encoding sarcomeric
proteins. Noninvasive imaging is central to the diagnosis of HCM and cardiovascular magnetic resonance (CMR) is
increasingly used to characterize morphologic, functional and tissue abnormalities associated with HCM. The
purpose of this review is to provide an overview of the clinical, pathological and imaging features relevant to
understanding the diagnosis of HCM. The early and overt phenotypic expression of disease that may be identified
by CMR is reviewed. Diastolic dysfunction may be an early marker of the disease, present in mutation carriers prior
to the development of left ventricular hypertrophy (LVH). Late gadolinium enhancement by CMR is present in
approximately 60% of HCM patients with LVH and may provide novel information regarding risk stratification in
HCM. It is likely that integrating genetic advances with enhanced phenotypic characterization of HCM with novel
CMR techniques will importantly improve our understanding of this complex disease.
Introduction
Hypertrophic cardiomyopathy (HCM) is the most com-
mon heritable cardiovascular disorder, with a prevalence
of 1:500 in the general population. It is also the most
common cause of sudden cardiac death (SCD) in young
individuals and young athletes [1,2]. HCM is an autoso-
mal dominant disease caused by mutations in genes
encoding sarcomere proteins [1]. Autosomal recessive,
X-linked, and mitochondrial (matrilinear) patterns of
inheritance also occur [1,3]. The penetrance of left ven-
tricular hypertrophy (LVH) is highly age-dependent and
incomplete [4]. Although the most common expression
of HCM is during adolescence [5,6], patients may present
at any point in life. Clinical screening of first-degree rela-
tives is recommended annually during adolescence (age
12-18) [7]. Adult relatives of HCM affected individuals
beyond age 18 may be screened at 5 year intervals.
The annual mortality rate of HCM ranges from < 1% in
the general community to 3-6% in tertiary referral cen-
ters [1,8]. Current risk factor stratification for SCD
considers multiple factors, including nonsustained ventri-
cular tachycardia, syncope, exercise blood pressure
response, family history of sudden death, high risk
genetic mutations as considered in individual patients
[7,9,10]. On the imaging level, risk factors for SCD in
HCM include left ventricular (LV) wall thickness and left
ventricular outflow tract (LVOT) obstruction (Table 1).
The diagnosis of HCM is based largely on imaging
features. Noninvasive diagnosis is based on left ventricu-
lar (LV) wall thickness ≥ 15 mm at end-diastole (fre-
quently involving the interventricular septum) or septal
to lateral wall thickness ratio higher than 1.3 in a non-
dilated LV in the absence of a loading condition suffi-
cient to cause the observed abnormality [5,11,12]. How-
ever, Maron et al., [1] have stated that virtually any LV
wall thickness, even when within normal limits, can be
consistent with the presence of an HCM-causing mutant
gene. Further, only one major CMR manuscript has
focused on establishing normal values for LV wall thick-
ness using current steady state free precession (SSFP)
pulse sequences at 1.5 T (Dawson, Dawson et al. Circ
Cardiovasc Imaging 2011 [13]) in 60 men and 60
women Caucasian subjects. In that study, wall thickness
was evaluated only on short axis views.
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diac magnetic resonance (CMR) for the diagnosis of
HCM because of its precise determination of myocardial
anatomy and the depiction of myocardial fibrosis. The
purpose of this review is to provide the physician with a
review of clinical, pathologic and genetic abnormalities
relevant to understanding the potential role of CMR in
HCM.
Pathologic basis of HCM
The diagnosis of HCM was historically made by pathol-
ogists only at the untimely death of an individual [14].
Advances in cardiovascular imaging and genetics have
facilitated improved diagnosis allowing for deployment
of interventions such as intracardiac defibrillators that
can favorably alter the natural history of the disease in
high risk patients. HCM in living individuals is seen by
pathologists on septal myectomy, endomyocardial
biopsy, left ventricular core from assist device place-
ment, and cardiac explant specimens. Rarely is this the
primary diagnostic modality for HCM.
Grossly, the defining feature of an HCM heart is
increased LV mass and thickened wall, especially the
interventricular septum [15]. Grossly-evident scattered
fibrosis may or may not be present. In some cases, there
is a predilection for fibrosis at the junction of the sep-
tum to the anterior and posterior walls of LV. The
thickened septum often bulges into LV, diminishing the
LV end diastolic lumen space. When prominent this
septal bulge may dynamically block left ventricular out-
flow. When this obstruction occurs, anterior displace-
ment of the papillary muscles/mitral leaflets occurs and
t h ea n t e r i o rl e a f l e to ft h em i t r a lv a l v er u b st h es e p t a l
wall upon opening resulting in endocardial thickening,
noted as a pearly white alteration along the outflow
tract. These abnormalities may lead to altered hydrody-
namic forces resulting in systolic anterior motion (SAM)
of the mitral valve and mitral leaflet-septal contact with
obstructive physiology [16]. Eventually, the valve leaflets
and chordae tendineae become thickened by fibrosis
[14,17].
The key histologic feature of HCM is myocyte and
myofibrillar disarray [15,16]. Myocyte disarray is non-
linear or haphazard arrangement of the myocytes
observed by light microscopy. Typically, “herringbone”
or “pinwheel” configurations are noted [15]. Various
papers have suggested a need for a minimal amount of
myocyte disarray (usually 5 or 10%) to make the diagno-
sis of HCM [18,19]. This is because rare myocyte disar-
ray can occur in other diseases or even in normal hearts
where two muscle bundles come together [15].
In addition to disarray, three other non-specific find-
ings are generally noted in HCM. One is obvious myo-
cyte hypertrophy with nuclear enlargement, angulated
nuclear borders and hyperchromasia. A second is a
marked increase in both interstitial and replacement
fibrosis that may be patchy of diffuse, mainly in the sep-
tal region [20]. The third is dysplasia of small arteries,
seen as medial and intimal smooth muscle cell prolifera-
tion with luminal narrowing [21]. Small vessels are
encased by dense perivascular collagen and also contain
increased collagen within the media. Reduced arteriolar
density may lead to small-vessel intramural coronary
artery disease (SICAD) as an early manifestation of
HCM [22]. This dysplasia is more prevalent in areas of
replacement fibrosis. This suggests reduction in blood
flow contributes to regional myocyte loss as a substrate
for ventricular arrhythmia and subsequently SCD [1,21].
Taken together, mid-septal myocyte disarray with myo-
cyte hypertrophy, fibrosis, dysplastic small coronary
arteries, and endocardial thickening are the histopatho-
logic hallmarks of HCM.
Morphologic variants identified by noninvasive imaging
Multiple morphological variants of HCM have been
described that can be identified by cardiac magnetic
resonance (CMR). These are detailed below:
Asymmetric HCM with sigmoid septal contour ("septal
HCM”)
This is the most common morphologic presentation
HCM, accounting for about two thirds of the spectrum
[23,24]. Hypertrophy of the anteroseptal myocardium
Table 1 Major risk factors for the assessment of sudden cardiac death in hypertrophic cardiomyopathy* (adapted
from [7])
Major risk factors Possible risk factors in
individual patients
Cardiac arrest/ventricular fibrillation or spontaneously occurring and sustained VT Atrial fibrillation
Family history of premature HCM-related sudden death Left ventricular outflow obstruction
Left ventricular thickness equal to or greater than 30 mm, especially in adolescents and young adults Intense physical exertion
Abnormal upright exercise blood pressure response that is attenuated or hypertensive (of greater predictive
value in patients less than 50 yrs old or if hypotensive)
High risk gene mutation
Nonsustained ventricular tachycardia by Holter examination
Unexplained syncope, especially in young patients or when recurrent or exertional
*risk factor assessed by imaging.
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As indicated above, these abnormalities may lead to
altered hydrodynamic forces resulting in SAM of the
mitral valve and mitral leaflet-septal contact with
obstructive physiology [16]. This results in subaortic
obstruction and a concomitant mitral regurgitant jet
(Figure 1 B, b) directed posteriorly into the left atrium
(LA) due to incomplete leaflet apposition. Peak instanta-
neous outflow tract gradients can be estimated using
phase-contrast CMR [25,27]. Anterior and posterior
mitral valve leaflet length in HCM are greater than in
control subjects by CMR (26 ± 5 versus 19 ± 5 mm, P <
0.001; and 14 ± 4 versus 10 ± 3 mm, P < 0.001, respec-
tively). This anatomic feature has been postulated to be
responsible for LVOT obstruction [28].
Asymmetric HCM with reversed septal contour
In this form, the septum hypertrophies as a reversed S-
type curve (Figure 1 C, c) that does not cause LVOT
obstruction [24,29,30]. LV mass may not be increased in
patients with asymmetric HCM, especially with focal
hypertrophy involving less than two LV segments
[24,31]. Subtle evidence of regional wall hypocontracti-
lity may be present despite a normal LV ejection frac-
tion (EF). Systolic function declines as LVH becomes
more severe [24,30].
Asymmetric HCM is identified on short axis images
characterized by a septal: free wall thickness ratio > 1.3
[15].
HCM with mid-ventricular obstruction (with or without a LV
apical diverticulum)
In this variant, there is marked mid-ventricular hyper-
trophy (Figure 1 D, d) together with mid-cavity narrow-
ing giving a ‘dumb-bell’ configuration of LV [27,29]. In
severe cases of narrowing, apical dilatation may occur.
The apical dilatation is thought to result from the gen-
eration of increased systolic pressures within the cardiac
apex due to mid-ventricular obstruction [15,27].
In approximately 10% of patients, there is progression
to a “burned out apex” with apical aneurysm formation
and late gadolinium enhancement (LGE) after gadoli-
nium administration [32]. This appearance is thought to
result from ischemia resulting from reduced capillary
density, hyperplasia of the arterial media, increased peri-
vascular fibrosis and myocardial bridging [15,33].
Apical HCM
In apical HCM, there is obliteration of LV cavity at the
apex, giving a characteristic spade-like configuration of
the cavity [34] seen on vertical long axis views (Figure 1
E, e). An apical wall thickness of > 15 mm or a ratio
between apical and basal LV wall thicknesses ≥ 1.3-1.5
are characteristically present [35,36]. This variant is
more frequent in the Japanese population (~25% of
HCM patients) compared to western countries (~2% of
HCM patients) [24,35].
CMR is particularly helpful in identifying apical HCM.
In 10 patients with apical HCM by CMR (including one
with LV wall thickness of 28 mm), echocardiograms
were consistently negative [35]. Other comparisons of
CMR to echocardiography for HCM diagnosis are
shown in Table 2.
Symmetric (Concentric) HCM
In up to 42% of HCM cases, hypertrophy symmetrically
involves the ventricular wall with no regional prefer-
ences (Figure 1 F, f). LV cavity dimensions are reduced
in a concentric fashion [26,29]. Symmetric LVH in the
absence of hypertension or aortic stenosis may also be
present in a variety of disorders, including amyloidosis,
sarcoidosis and Fabry’s disease. Hypertrophy in the ath-
lete’s heart is typically relatively modest, LV cavity size
is normal to enlarged (as compared to the typically
small LV cavity seen in HCM), and there is no evidence
of diastolic dysfunction nor LGE. These features help to
distinguish athlete’s heart from symmetric HCM [8].
Focal HCM
Patients with HCM occasionally present with focal,
mass-like thickening of LV. In these cases, CMR may
help distinguish HCM from other cardiac masses using
CMR tagging by spatial modulation of magnetization
(SPAM)[37]. Tag lines show evidence of myocardial
contractility in HCM, whereas neoplastic masses should
not be contractile [38]. In addition, the signal intensities
of tumor-related masses in the myocardium on spin
echo CMR, first-pass perfusion and LGE-CMR are fre-
quently different from normal myocardium [29]. The
CMR characteristics of tumor-like HCM more closely
resemble that of adjacent normal myocardium.
Right ventricular (RV) involvement in HCM
RV hypertrophy has been reported in approximately
18% of HCM patients [24,29]. This typically involves the
mid-to-apical portion of the RV. Severe involvement of
the RV may result in RV outflow obstruction or reduced
RV diastolic filling [15].
Genotype-phenotype correlations in HCM
Although several echocardiographic studies have evalu-
ated the relationship between various morphologic sub-
types and sarcomeric mutation [39,40], such
relationships are controversial and need further study.
Sigmoidal HCM appears to be most common in the
elderly and less likely to have an underlying sarcomere
mutation.
In a cohort of 382 HCM patients, 73% of patients with
sarcomeric HCM had reversed curve septum while only
10% had sigmoid septum. The incidence of SCD was
found to be higher in specific MYH7 mutations [41].
Progression to heart failure was reported to be more
commonly associated with mutations in MYH7 and
TNNI3 than from other HCM mutations [42,43]. One
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reported in at least 5 families with either apical hyper-
trophy or LV noncompaction [44,45]. Approximately 3-
5% of HCM patients may have multiple mutations (i.e.,
compound or digenic heterozygosity). These patients
often have a more severe phenotype and increased
Figure 1 Left ventricular patterns in HCM, each drawing is accompanied by its corresponding image, (A, a) normal LV, (B, b) sigmoid
septum showing SAM of mitral valve (white arrow), (C, c) reversed septal contour, note that there is no signs of LVOT, (D, d) mid
ventricular hypertrophy, (E, e) Apical HCM, (F, f) symmetric HCM.
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effect might contribute to disease severity. Most cases of
compound heterozygosity involve MYBPC3 [46]. A
recent report highlights the consequences of HCM
resulting from 3 distinct mutations [49]. These investi-
gators identified 4 such cases among 488 unrelated
HCM probands (0.8%). Three of the 4 had severe dis-
ease that progressed to end-stage HCM by the fourth
decade.
Increased left ventricular mass in HCM
LVH is widely regarded as a requirement for clinical
diagnosis of HCM [30,50,51]. However, recent geno-
type-phenotype correlations have shown that virtually
any wall thickness may be found in patients with a
HCM gene mutation [24]. Greater CMR defined LV
mass is associated with less favorable clinical outcome.
This is attributed to the relationship between LVH and
both the presence of LVOT obstruction and more
advanced heart failure [52,53]. Olivotto et al. [30]
demonstrated that LV mass index is a more sensitive
indicator for risk of death than peak wall thickness.
CMR provides better diagnostic accuracy than echo-
cardiography in definition of the ventricular size, magni-
tude and distribution of hypertrophy, especially in
identification of the anterolateral wall of LV [23,35,54].
Therefore, assessment of LV mass using CMR plays an
important role in risk stratification of the disease.
Assessment of diastolic function
Diastolic dysfunction (DD) is an early functional marker
of HCM. DD occurs secondary to abnormal dissociation
of actin and myosin filaments during the active phase of
relaxation in early diastolic filling [55,56]. The assess-
ment of diastolic function with CMR using myocardial
tissue tagging has been previously reviewed [57]. Passive
late diastole filling is also impaired due to increased
interstitial fibrosis. Myocyte disarray may affect both
ventricular relaxation and stiffness [55,58]. Shirani et al.,
[33] suggested that the expanded and disorganized
architecture of collagen matrix may contribute to DD.
This results in decreased peak filling rate (PFR) and
increased time to PFR [59,60]. With diastole, prolonga-
tion of isovolumic relaxation is thought to be an early
and sensitive marker of DD [61].
Tissue Doppler echocardiographic studies on geno-
typed subjects have demonstrated that sarcomere muta-
tion carriers have diastolic abnormalities early in life,
prior to the development of LVH. Impaired relaxation
can be detected as decreased early myocardial relaxation
velocities [62-64]. These studies indicate that diastolic
abnormalities are an early, potentially, direct manifesta-
tion of the underlying sarcomere mutation, rather than
simply a secondary consequence of altered myocardial
compliance characteristics due to the hypertrophy, fibro-
sis and disarray that accompanies development of clini-
cally overt disease.
Different CMR methods can be used to assess diasto-
lic dysfunction. The first approach aims to parallel mea-
sures used by other imaging modalities [55,56].
Ventricular time-volume curves can provide accurate
assessment of global diastolic function. From these, PFR
and time to PFR can be estimated [58]. PFR may be
“normalized” relative to end-diastolic volume (PFR/
EDV) and to stroke volume (PFR/SV). Unfortunately,
PFR is only partially representative of compliance
[56,59]. Mitral inflow velocities (early filling “E” and
atrial systolic filling” A”) and pulmonary vein flow (sys-
tolic “S” and diastolic “D” velocities) derived from phase
contrast CMR (PC-CMR) provide highly reproducible
and accurate data. Velocity data can be used to calculate
pressure gradients (ΔP) using the modified Bernoulli
equation (ΔP=4 V
2, where V = velocity) to classify DD
[55]. Finally, myocardial motion velocity may be evalu-
ated by PC-CMR. This approach can acquire images in
multiple oblique planes, allowing the operator to choose
Table 2 Accuracy of CMR for detection of HCM in comparison to 2-dimensional echocardiography
Authors Year Journal Number of
patients
% of HCM patients detected
by MRI only
Location of CMR detected abnormality
Maron et al.
[24]
2009 Journal of the American
College of Cardiology
333 12% Anterolateral free wall, posterior portion of
septum, LV apex
Maron et al.
[108]
2007 Circulation 2 100% Anterior free wall
Rickers et al.
[23]
2005 Circulation 48 6% Anterolateral free wall
Moon et al.
[35]
2004 Heart 10 100 Apical
Pons-Llado
et al.[109]
1997 Am. Journal of Cardiology 30 Echocardiography
underestimated wall thickness
Anterior basal, septal anterior mid-ventricular,
lateral mid-ventricular
Posma et al.
[110]
1996 American Heart Journal 52 Echocardiography
underestimated wall thickness in
37%.
Anterobasal septum, anterolateral wall,
posteroseptal wall, apical septum, posterior wall
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a high spatial and temporal resolution [65].
The second CMR approach to assess diastolic function
is to directly measure myocardial diastolic relaxation. LV
strain rate and torsion recovery rate are assessed using
myocardial tissue tagging [56]. Tagged CMR can assess
regional myocardial mechanics at different time-points
during the cardiac cycle [66]. Reduced early diastolic
strain rates are present in hypertrophied segments [67].
CMR tagging shows decreased relaxation rate and
diminished early diastolic filling velocity as a result of
delayed and prolongation of diastolic untwisting [66].
Assessment and quantification of myocardial fibrosis
Myocardial fibrosis or scaring detected by CMR occurs
in up to 33-86% of patients with HCM [30,53,68,69].
LGE-CMR characteristics are not specific for HCM, but
the regional location of diffuse LGE within the septum
is very suggestive of HCM [16].Table 3 shows incidence
of LGE in multiple studies focused on HCM. The
weighted mean reported prevalence of LGE, in 1814
LVH positive HCM patients, is 65% (Table 3).
T h ep r o g n o s t i cs i g n i f i c a n c eo ft h epresence of LGE in
HCM to adverse outcome is high. The presence of LGE
in HCM patients has been associated with sudden car-
diac death, systolic dysfunction and nonsustained ventri-
cular tachycardia [69-73]. Table 4 lists studies that have
evaluated the relationship between presence of LGE and
various outcome parameters. Although the extent
(rather than the presence) of fibrosis also was a predictor
of major arrhythmic events, the degree of fibrosis has
not yet been a significant predictor of events in multi-
variate analysis [73], possible due to small number of
study subjects with events. Pathologically, fibrotic tissue
is thought to be associated with re-entrant ventricular
arrhythmia as well as myocardial dysfunction. The sig-
nificance of LGE appears high, and larger, multi-center
longitudinal trials to assess its prognostic significance
seem warranted at this time.
Multiple factors have been proposed in the etiology of
myocardial fibrosis in HCM patients, although the true
origin has not yet been determined. Moon et al., [74]
found greater collagen deposition correlated directly
with LGE of the myocardium. Ho et al., [75] studied the
PICP: CITP ratio that reflects the balance between col-
lagen synthesis and degradation. They found a signifi-
cantly higher PICP: CITP ratio in subjects with overt
HCM compared to mutation carriers (without LVH)
and the control group. The authors hypothesized that in
overt HCM, collagen synthesis exceeds degradation,
resulting in frank myocardial fibrosis.
Alternatively, LVH and dynamic LVOT pressure gra-
dients may result in potential pressure necrosis causing
small-vessel intramural coronary artery disease (SICAD)
[21]. Ischemia may result from microvascular disease;
increased end diastolic pressure together with the
increased demand of LVH might initiate the processes
of myocyte death and replacement fibrosis as a repair
process [76].
Stress perfusion CMR m a yb ep e r f o r m e di ns a m es e t -
ting as a LGE CMR study [77,78]. The severity of myo-
cardial perfusion defects correlate with areas of maximal
Table 3 Incidence of late gadolinium enhancement (LGE) in HCM by CMR
Author Year Journal Number of patients % of patients with LGE
O’Hanlon et al. [73] 2010 Journal of the American College of Cardiology 217 63%
Bruder et al.[69] 2010 Journal of the American College of Cardiology 220 67.2%
Ho et al. [75] 2010 The New England Journal of Medicine 28 71%
Rubinshtein et al. [111] 2010 Circulation Heart Failure 424 56%
Kown et al. [68] 2009 Journal of the American College of Cardiology 60 63%
Rudolph et al. [76] 2009 Journal of the American College of Cardiology 36 72%
Maron et al. [84] 2008 Circulation Heart Failure 202 55%
Adabag et al. [70] 2008 Journal of the American College of Cardiology 177 40.6%
Kwon et al. [112] 2008 International J. of Cardiovascular Imaging 68 57%
Abdel Aty et al. [93] 2008 Journal of Magnetic Resonance Imaging 27 33%
Paya et al. [113] 2008 Journal of Cardiac Failure 120 69%
Melacini et al. [114] 2008 International Journal of Cardiology 44 80%
Kim et al. [115] 2008 Journal of Magnetic resonance Imaging 25 84%
Debl et al. [116] 2006 Heart 22 73%
Soler et al. [117] 2006 Journal of Computed Assisted Tomography 53 56.6%
Teraoke et al. [82] 2004 Magnetic Resonance Imaging 59 76.3%
Bogaert et al. [83] 2003 American Journal of Roentgenology 11 63.6%
Choudhury et al. [71] 2002 Journal of the American College of Cardiology 21 81%
Summary LGE reports: Late enhancement 1814 65% [range, 33-84%]
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in patients with HCM [79]. These studies suggest that
microvascular abnormalities precede and predispose to
the development of myocardial fibrosis. When present,
perfusion abnormalities may represent an early risk mar-
ker and a possible therapeutic target [80].
Patterns of LGE in HCM
LGE in HCM characteristically appears as small punctu-
ate, patchy mid-wall hyper-enhancement [29,71]. There
is a predilection to occur at the anterior and posterior
RV insertion points (Figure 2). These RV insertion
points represent plexiform fibrosis containing the cross-
ing-fibers of LV and RV [80-82], although this pattern is
not specific for HCM (e.g. patients with right ventricular
hypertrophy also may demonstrate LGE at these sites).
The interventricular septum is commonly involved by
LGE, particularly the anteroseptal mid to basal segments
(Figure 2). These segments are also the most commonly
thickened segments, especially in patients with asym-
metric HCM [81,82]. Other foci of LGE are described as
noncoronary in distribution, tending to occur in the
hypertrophied regions (Figure 3) [29,71]. An exception
to this is areas of burned out HCM where the LV wall
is typically thinned and full thickness LGE is present
[83].
In a cohort of 202 HCM patients; Maron et al., [84]
showed that LGE was most commonly located in both
the ventricular septum and LV free wall. Less frequently,
LGE was confined to the LV free wall, followed by the
septal LGE. The least common sites were the RV inser-
tion into the ventricular septum followed by the LV
apex. In patients without LVH, it is unusual to find LGE
by CMR. This suggests that LGE occurs after develop-
ment of LVH [85].
The pattern of LGE may be useful in distinguishing
HCM from Anderson-Fabry disease [86,87]. Anderson-
Fabry disease is an x-linked disorder of sphingolipid
metabolism associated with LVH. In one series, 50% of
patients had LGE [86]. The most common location of
LGE was in the basal inferolat e r a lw a l l( 1 2 / 1 3p a t i e n t s )
in a non ischemic pattern. The basal inferolateral wall is
an infrequent location of isolated LGE for HCM.
Functional implications of late gadolinium enhancement
The presence and extent of LGE in relation to impaired
ejection fraction (EF) is unclear. Some investigators
found no significant relationship [76], but others have
shown percent of LV involvement by LGE inversely cor-
relates with LV function [84]. LGE may be associated
with increased myocardial stiffness and LV adverse
remodeling leading to cavity dilatation and eventually
systolic dysfunction [72]. A larger extent of LGE is asso-
ciated with higher incidence of regional wall motion
abnormalities [35,74]. In the presence of LVOT obstruc-
tion, there was no significant relationship between
extent of LGE and magnitude of LV outflow gradient at
rest [76,84].
Table 4 Relationship between presence of late gadolinium enhancement (LGE) and clinical cardiac events in HCM
Study Number
of
patients
% of study
population
with LGE
Event Rate
Positive LGE versus
Negative LGE
groups
Hazard ratio
(HR) or relative
risk (RR)
Primary endpoint
O’Hanlon et
al. 2010 [73].
217 63 24.5% LGE+ vs. 9.9%
LGE- had primary
endpoint
HR 3.4 [1.4-8.1] Cardiovascular death, unplanned cardiovascular admission,
sustained ventricular tachycardia or ventricular fibrillation,
appropriate implantable cardioverter-defibrillator discharge
Rubinshtein
et al. 2010
[111].
424 56 3.3% of LGE+
patients had SCD/ICD
n/a Sudden cardiac death and appropriate implanted cardioverter
defibrillator (ICD) discharge
Bruder et al.
2010 [118]
220 67.2 94% LGE+ vs. 66%
LGE- had primary
endpoint
HR 8.0 [1.0-61.9] Sudden cardiac death and appropriate implanted cardioverter
defibrillator (ICD) discharge.
Adabag et
al. 2008 [70]
177 40.6 28% LGE+ vs. 4%
LGE- w/NSVT
RR 7.3 [2.6-20.4] Nonsustained ventricular tachycardia (NSVT) by Holter monitor
Paya et al.
2008 [113]
120 69 38% LGE+ vs. 8%
LGE- had NSVT (p <
0.05)
not indicated Nonsustained ventricular tachycardia (NSVT) by Holter monitor
Suk et al.
2008 [119]
25 64 88% LGE+ vs. 53%
LGE- had VT (p <
0.05)
not indicated Ventricular tachycardia by Holter or resting ECG
HF: Heart failure
ICD: intra-cardiac defibrillator.
NSVT: Non-sustained ventricular tachycardia
OR: Odds ratio.
PVCs: Premature ventricular contractions
VT: Ventricular tachycardia
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High-resolution T1 mapping is an emerging technique
for detection and quantification of subtle myocardial
fibrosis. Abnormal T1 longitudinal relaxation may be
useful to quantify the pathologic state of the tissue
[88,89]. T1 times are not specific for individual tissues,
but each tissue has a normal range that varies by field
strength [88,90]. In patients with heart failure, myocar-
dial segments with diffuse fibrosis showed shorter T1
time compared to segments with no LGE [91]. This
technique may have potential for evaluation of HCM
patients.
Following gadolinium administration in patients with
HCM, Amano et al. [92] confirmed that T1 times of
hyperenhanced regions of myocardium were lower than
remote regions in the same patients. However, the
remote regions without visually detected hyperenhance-
ment had altered T1 time compared to a normal control
population. This study suggests that T1 mapping may
have a role in quantitative characterization of myocardial
tissue in HCM. Since the method may detect diffuse
fibrosis that is not visually detected, T1 mapping may be
applicable to subclinical HCM, discussed further below.
T2 weighted sequences in HCM
High T2 signal intensity has been reported in HCM
patients, frequently corresponding to LGE regions in
HCM cases [93]. High T2 signal related to edema may
accompany focal ischemia due to SICAD [94,95]. The
spatial relation between high T2 signal intensity and
LGE could be explained by the pathologic progression
of fibrosis: this may start with acute ischemia or inflam-
mation (high T2 signal), and ending with mature
chronic fibrous tissue (no obvious T2 abnormalities)
[93,96].
Other CMR applications in HCM
Myocardial disarray can be quantified with diffusion
CMR [97], either by measuring the myocardial diffusion
anisotropy, which is directly correlated with myocardial
Figure 2 Late gadolinium enhancement patterns involving the anterior and posterior RV insertion points, as shown; the
interventricular septum is involved, particularly the anteroseptal basal segment (three arrow heads).
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Tseng, et al. [99] found significant reduction of diffusion
anisotropy in the hypertrophied septum due to an
increase in the longitudinally oriented fibers. Rippplinger
et al. evaluated a transgenic rabbit model of human
hypertrophic cardiomyopathy. They reported that myo-
cardial fiber anisotropy was similar in the wild type
compared to the transgenic animal models [100]. Lim-
itations of diffusion CMR include limited spatial resolu-
tion, motion artifact and long imaging times.
CMR spectroscopy can be used to measure the ratio
of PCr/ATP that reflects the energy status of the myo-
cardial tissue. Decreased PCr/ATP was associated with
the extent of hypertrophy and disturbed diastolic func-
tion in both symptomatic [101] and asymptomatic
patients [102]. Shivu et al. showed PCr/ATP ratio was
significantly reduced in HCM patients compared to con-
trols [103]. Perhexiline, a modulator of substrate meta-
bolism, was shown to signifi c a n t l yi n c r e a s eP C r / A T P
ratios in HCM patients [104]. Current limitations of
CMR spectroscopy including low spatial resolution, long
scan time and special coils.
Role of CMR in early detection of negative phenotypes
(pre-clinical HCM)
For the reason that SCD may be the first symptom of
HCM [105], there is substantial interest in early identifi-
cation of HCM mutation carriers who may be at risk for
life-threatening events [72,82]. Patients with pre-clinical
HCM are negative for LVH, but are genetically positive
for the disease. Because CMR accurately presents both
anatomic and functional characteristics of HCM, its role
in pre-clinical HCM is potentially relevant. To date,
most imaging studies of pre-clinical HCM have been
based on echocardiography.
Germans et al. [6] evaluated asymptomatic HCM car-
riers by CMR. They described LV crypts, best visualized
at end-diastole, even when LV wall thickness was nor-
mal. However, Maron et al.[106] also described a deep
LV crypt penetrating 12 mm into a hypertrophied basal
Figure 3 Patchy mid wall, variable sized foci of hyperenhancement in a non-coronary distribution, involving mainly the hypertrophied
parts (arrow heads). Right ventricle is also hypertrophied (large arrows).
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Page 9 of 13posterior portion of ventricular septum of a patient with
overt HCM. The significance of LV crypts in HCM
remains unclear.
Diastolic function assessed by echocardiography has
been reported to be abnormal in pre-clinical HCM
[107]. This finding has not been studied by CMR. In
addition, tissue characterization by MR spectroscopy or
T1 mapping is yet to be explored in preclinical HCM.
Conclusions
CMR appears to be highly relevant in the clinical as well
as research evaluation of patients with overt as well as
pre-clinical HCM. Late enhancement after gadolinium
administration allows tissue characterization of myocar-
dial fibrosis. The method may potentially identify HCM
patients at greatest risk for adverse cardiac events. CMR
evaluation of HCM mutation carriers in an early stage
of disease has yet to be extensively evaluated, but repre-
sents a promising method for exploring the inter-rela-
tionship between functional, morphologic and tissue
abnormalities in HCM.
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